• Wed. Sep 28th, 2022

shoosh infosite

s….s INFO

David Denning

Byarticle

Dec 16, 2021

David W. Denning is a British retired professor of infectious diseases and global health and medical mycology at Wythenshawe Hospital and the University of Manchester. He is the founding president, executive director and chief executive of the Global Action Fund for Fungal Infections (GAFFI), which focusses on the global impact of fungal disease.

David W. Denning
Nationality British
Education Guy’s Hospital
Known for Founding president of the Global Action Fund for Fungal Infections
Medical career
Profession Physician
Field Infectious diseases
Institutions
Research Fungal infection

He became the director of the UK’s National Aspergillosis Centre in Manchester, which treats people with chronic pulmonary aspergillosis (CPA), and led the group that produced the first guidelines for CPA in 2015. He retired from clinical practice in 2020.

. . . David Denning . . .

David Denning studied medicine at Guy’s Hospital, London, and graduated in 1980.[1] He then trained in internal medicine and infectious diseases in London and Glasgow.[1] Between 1985 and 1987 he had a research post with the Medical Research Council, before a three-year fellowship in diagnostic microbiology and infectious diseases at Stanford University, which he completed in 1990.[1]

He became professor of infectious diseases and global health and medical mycology at Wythenshawe Hospital and the University of Manchester.[1] In 2009 he became the director of the UK’s National Aspergillosis Centre in Manchester, which treats people with CPA.[2][3] He is the founding president, executive director and chief executive of the GAFFI, which focusses on the global impact of fungal disease.[1][4] Denning led the group that produced the first guidelines for CPA in 2015.[5] He chairs the editorial board of a website which focusses on aspergillus and he leads an organisation which provides education on fungal diseases.[2]Antifungal medications that he has contributed to research in include itraconazole, voriconazole, amphotericin B, caspofungin, and micafungin.[1] He founded two spinout biotechnology companies.[2] In 2020 he retired from clinical practice.[2]

. . . David Denning . . .

This article is issued from web site Wikipedia. The original article may be a bit shortened or modified. Some links may have been modified. The text is licensed under “Creative Commons – Attribution – Sharealike” [1] and some of the text can also be licensed under the terms of the “GNU Free Documentation License” [2]. Additional terms may apply for the media files. By using this site, you agree to our Legal pages . Web links: [1] [2]

. . . David Denning . . .